Company Summary: 180 Life Sciences Corp.

Overview:

• 180 Life Sciences Corp. is a biotechnology company focused on developing therapeutics for autoimmune and inflammatory diseases.
• The company has a specific focus on its α7nAChR platform, which relates to neurological and immunological research.

Corporate Structure & History:

• Formed through a business combination that closed on November 6, 2020, involving KBL and several subsidiaries, including 180, Katexco Pharmaceuticals, CannBioRex Pharmaceuticals, and 180 Therapeutics.
• The company’s headquarters is located in Palo Alto, California.
• Its legal structure is a Delaware corporation with IRS Employer Identification No. 90-1890354.

By the Numbers (as of March 31, 2025):

• Total shares issued and outstanding: approximately 5,185,780 shares of common stock, including 1,318,000 shares issuable upon conversion of Series B Convertible Preferred Stock (being issued on April 1, 2025).
• Market value of outstanding shares held by non-affiliates (as of last completed second fiscal quarter): approximately $1,548,662.

Securities:

• Common Stock traded on Nasdaq Capital Market under the symbol: ATNF
• Warrants to purchase shares of common stock traded under the symbol: ATNFW

Employees & Management:

• The company has a small executive team, including:
  • Blair Jordan, CEO and Director, age 56
  • Eric R. Van Lent, Chief Accounting Officer, age 42

Financial Information:

• The filing does not include specific revenue, net income, or operational metrics.
• The document emphasizes that this is an Annual Report (Form 10-K), but no detailed financial data such as revenue, profit, or number of customers is provided in the excerpt.

Business Focus & Development:

• The company's primary activity is developing and commercializing therapeutics based on its α7nAChR platform.
• The company is engaged in research and development activities related to autoimmune, neurological, and inflammatory diseases.
• It promotes responsible corporate governance, risk oversight, and compliance, with a board divided into two classes for staggered terms.

Additional Details:

• The company claims to be a smaller reporting company and an emerging growth company.
• It is not a well-known seasoned issuer and is not required to file certain reports under SEC regulations.
• The company has a Board of Directors with diverse backgrounds including biomedical research, finance, and international business.

Note: Specific data about the number of customers, total revenue, and operational income are not provided in the document. The summary is based solely on the provided SEC filing excerpt.